APA (7th ed.) Citation

A, L., D, M., K, T., DJ, B., MT, W., DR, B., . . . DYC, H. (2025). CABOSEQ 3-Comparison of Cabozantinib versus Sunitinib Following First-Line Nivolumab- Ipilimumab for Metastatic Renal Cell Carcinoma: A Target Trial Emulation Using Real-World Data from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC). Clinical genitourinary cancer, 23(6), 102431. https://doi.org/10.1016/j.clgc.2025.102431

Chicago Style (17th ed.) Citation

A, Lemelin, et al. "CABOSEQ 3-Comparison of Cabozantinib Versus Sunitinib Following First-Line Nivolumab- Ipilimumab for Metastatic Renal Cell Carcinoma: A Target Trial Emulation Using Real-World Data from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC)." Clinical Genitourinary Cancer 23, no. 6 (2025): 102431. https://doi.org/10.1016/j.clgc.2025.102431.

MLA (9th ed.) Citation

A, Lemelin, et al. "CABOSEQ 3-Comparison of Cabozantinib Versus Sunitinib Following First-Line Nivolumab- Ipilimumab for Metastatic Renal Cell Carcinoma: A Target Trial Emulation Using Real-World Data from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC)." Clinical Genitourinary Cancer, vol. 23, no. 6, 2025, p. 102431, https://doi.org/10.1016/j.clgc.2025.102431.